Activator for Transient Receptor Potential Vanilloid 2 Comprising Probenecids

A method for isolating TRPV2 positive neurons comprising the following steps:

• 1) culturing the neurons isolated from a subject and treating them with probenecids;
• 2) measuring TRPV2 activity of the neurons treated in step 1);
• and,
• 3) selecting neurons which are positive to probenecids by comparing the TRPV2 activity measured in step 2) with the TRPV2 activity of neurons not-treated with probenecids.

A method for isolating TRPV2 negative neurons comprising the following steps:

• 1) culturing neurons isolated from a subject and treating them with probenecids and a non-specific TRPV2 activator stepwise in that order or in reverse order;
• 2) measuring the TRPV2 activity of the neurons treated in step 1);
• and
• 3) selecting neurons which are positive to the non-specific TRPV2 activator but negative to probenecids by comparing the TRPV2 activity measured in step 2) with that of the neurons not treated with probenecids and the non-specific TRPV2 activator, respectively.

A method for screening a TRPV2 blocker comprising the following steps:

• 1) treating TRPV2 positive neurons with probenecids and TRPV2 blocker candidates;
• 2) treating TRPV2 negative neurons with the above TRPV2 blocker candidates and a non-specific TRPV2 activator;
• 3) measuring the TRPV2 activities of both TRPV2 positive neurons treated in step 1) and TRPV2 negative neurons treated in step 2);
• and
• 4) selecting candidates which inhibit TRPV2 activity of TRPV2 positive neurons treated with probenecids and TRPV2 blocker candidates but do not affect the TRPV2 activity of TRPV2 negative neurons treated with the TRPV2 blocker candidates and the non-specific TRPV2 activator by comparing the TRPV2 activity of step 3) with that of TRPV2 positive neurons treated with probenecids alone.

A method for screening a TRPV2 blocker comprising the following steps:

• 1) constructing a transformant by transfecting a host cell with a plasmid containing polynucleotide encoding TRPV2;
• 2) treating the transformant with probenecids and TRPV2 blocker candidates;
• 3) treating TRPV2 negative neurons with the TRPV2 blocker candidates and a non-specific TRPV2 activator;
• 4) measuring the TRPV2 activities of both the transformant of step 2) and TRPV2 negative neurons of step 3);
• and,
• 5) selecting candidates which inhibit the TRPV2 activity of the transformant treated with probenecids and the TRPV2 blocker candidates but do not affect the TRPV2 activity of TRPV2 negative neurons treated with the TRPV2 blocker candidates and the non-specific TRPV2 activator by comparing each activity measured in step 4) with the TRPV2 activity of the transformant treated with probenecids alone.

A method for screening a TRPV2 blocker comprising the following steps:

• 1) treating a subject with probenecids and TRPV2 blocker candidates;
• 2) measuring nociceptive behaviors induced in the subject treated in step 1);
• and,
• 3) selecting candidates inducing nociceptive behaviors by comparing the nociceptive behaviors measured in step 2) with those of the subject treated with probenecids alone.